AAM Statement on President-elect Biden Naming Katherine Tai as U.S. Trade Representative
WASHINGTON, DC (December 10, 2020) — The Association for Accessible Medicines and its members look forward to working with President-elect Biden’s U.S. Trade Representative (USTR)-designee Katherine Tai to ensure that U.S. trade policy promotes the proper balance between pharmaceutical innovation and off-patent competition that expands patient access to medicines and reduces health care costs. USTR-designee […]
AAM Letter to President on “Buy American” Requirements
On Friday, March 27, 2020, AAM and 68 signatories signed on to a letter to President Trump expressing our opposition to proposed “Buy American” requirements that would make it harder for the U.S. government to purchase medicines produced using ingredients from outside the U.S — especially in the middle of a public health emergency. The […]
AAM Buy American Fact Sheet
A diverse, resilient supply chain for prescription medicine will moderate the risk of drug shortages and ensure patient access during the COVID-19 pandemic and beyond. Developers of generic and biosimilar medicines support diversification of the pharmaceutical supply chain — and incentives to increase manufacturing in the United States — but we must not hinder our […]
American Patients Must Tell Congress to Fix the USMCA to Lower Drug Prices!
Poll Results: Americans’ Attitudes on U.S. Trade Policy and Drug Pricing
WASHINGTON DC (November 14, 2018) – Republican and Democratic voters agree. Americans do not want the new U.S.-Mexico-Canada trade agreement (USMCA) to raise drug prices or decrease competition from more affordable generic or biosimilar medicines. The Association for Accessible Medicines joined 28 groups representing patients, taxpayers, workers and health care groups in submitting letters to […]
Patient Groups, Retirees, American Workers, Doctors, Manufacturers, Join to Voice Concern Over Proposed Trade Deal
Diverse Coalition Says USMCA Violates U.S. Law, Protects Drug Monopolies and Keeps Price of Medicine High, Hurting Patients and American Businesses WASHINGTON, DC (November 5, 2018)–Today the Association for Accessible Medicines (AAM), together with 28 groups representing patients, taxpayers, workers and health care groups, submitted letters to U.S. Trade Representative Robert E. Lighthizer, Health and […]
